The 13 most recent market catalysts affecting $LNTH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 75
Lantheus Announces Positive Results from Phase 3 Studies of TAUKLARIFY™ for Alzheimer's Disease
Lantheus announced that its investigational PET imaging agent, TAUKLARIFY™ (florquinitau F 18 injection), successfully met its primary endpoints in two pivotal Phase 3 studies for …
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 90
Lantheus Holdings, Inc. Reports Third Quarter 2026 Financial Results
Lantheus Holdings, Inc. has reported its third-quarter 2026 financial results. This event is highly significant because it provides the latest financial snapshot of the company jus…
Oct 13, 2026
Corporate Catalyst
Bearish
Impact 65
Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109
Mizuho analyst Anthony Petrone downgraded Lantheus Holdings (LNTH) from 'Outperform' to 'Neutral' and lowered the price target from $115 to $109. This action indicates a less optim…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1
Lantheus announced that its PYLARIFY TruVu injection has received Transitional Pass-Through (TPT) payment status from the Centers for Medicare & Medicaid Services (CMS), effective …
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
Lantheus Holdings Inc. announced FDA approval for its radiodiagnostic agent, Tauklarify (florquinitau F 18 injection), for PET scans to identify tau neurofibrillary tangle patholog…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
Lantheus Holdings announced the FDA approval of TAUKLARIFY, a radiodiagnostic agent for identifying tau neurofibrillary tangle pathology in adults with cognitive impairment being e…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Lantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate
Lantheus Holdings announced Q2 adjusted EPS of $1.55, significantly surpassing the $1.30 analyst consensus, and sales of $388.2 million, also beating the $362.416 million estimate.…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
Truist Securities analyst Richard Newitter downgraded Lantheus Holdings (LNTH) from a 'Buy' to a 'Hold' rating and significantly lowered the price target from $125 to $102.5. This …
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 65
TD Cowen Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
TD Cowen analyst Tara Bancroft downgraded Lantheus Holdings (LNTH) from a 'Buy' to a 'Hold' rating and lowered the price target from $110 to $102.5. This action indicates a less op…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 95
Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders
This 8-K filing discloses a definitive agreement for Curium, backed by CapVest Partners, to acquire Lantheus Holdings Inc. for up to $8 billion. This is a major corporate catalyst …
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on Lantheus Holdings, Lowers Price Target to $115
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Lantheus Holdings (LNTH), signaling continued confidence in the company's prospects. However, the price target w…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $120
Mizuho analyst Anthony Petrone maintained a 'Market Outperform' rating for Lantheus Holdings and raised the price target from $115 to $120. This action signals continued bullish se…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.